Total
0
Shares
Avita Therapeutics (ASX:AVH) - CEO, Dr Michael Perry - The Market Herald
CEO, Dr Michael Perry
Source: CNBC Television
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Avita Medical (AVH) reported a 126-per-cent revenue increase and steady growth in procedural volumes in its review of the March quarter
  • Revenue clocked in at $8.8 million for the period ending March 31 as procedural volumes reached 492 compared to 408 in the same period last year
  • Gross margins were down 76 per cent for the quarter, while operating expenses were also trimmed from $19.7 million in the prior corresponding period to $13.2 million
  • Despite an uplift across some performance metrics, the ASX-lister returned a net loss of $6 million, albeit an improvement on the $15 million loss incurred in the prior corresponding period
  • Avita Medical shares are up 2.72 per cent following the announcement, trading at $5.29

Avita Medical (AVH) reported a 126-per-cent revenue increase and steady growth in procedural volumes in its review of the March quarter.

The regenerative medical company's revenue clocked in at $8.8 million for the period ending March 31, representing a significant increase on the prior corresponding period's total of $3.8 million.

as procedural volumes reached 492 compared to 408 in the same period last year.

AVH's gross margin was 76 per cent for the third quarter of 2021, compared with 84 per cent in the same quarter last year, while operating expenses were brought down to $13.2 million compared to $19.7 million in the prior corresponding period.

Avita attributed the decrease in expenses is to lower stock-based compensation along with lower sales and marketing expenses, which were partially offset by higher costs in research and development.

Despite an uplift across some performance metrics, the ASX-lister returned a net loss of $6 million, albeit an improvement on the $15 million loss incurred in the prior corresponding period.

The company reported a cash balance of $114.9 million as of March 31, which included $64 million net proceeds from its capital issuance closed in the third quarter of 2021.

Avita Medical shares are up 2.72 per cent following the announcement, trading at $5.29 at 3:04 pm AEST.

AVH by the numbers
More From The Market Herald
Gabon-focussed iron ore company Genmin (ASX:GEN) lists on ASX

" Argenica Therapeutics (ASX:AGN) lists on ASX

Argenica Therapeutics (AGN) has finished its first day of trade on the ASX, following a well supported initial public offering.
Creso Pharma (ASX:CPH) - Creso Pharma - The Market Herald

" Creso Pharma (ASX:CPH) completes US dual listing

Creso Pharma (CPH) is officially dual listed, after completing its listing on the US OTCQB stock exchange.
The Market Herald Video

" US regulator approves expanded use of Avita Medical’s (ASX:AVH) RECELL System

The US regulator has approved the expanded use of Avita Medical’s (AVH) RECELL system in combination with meshed autographs to treat burns patients.
Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac - The Market Herald

" Advanced Human Imaging (ASX:AHI) signs term sheet with Cubert

Advanced Human Imaging (AHI) has signed a binding term sheet with Toronto-based digital health provider Cubert Inc.